8 Gynecologic (ovary, endometrial, cervix, fallopian tube) 16 Sarcoma/GIST 10 Thyroid 5 Neuroendocrine 4 Thoracic (NSCLC, mesothelioma) 3 Skin (melanoma, squamous, basalosquamous) 4 CUP (epithelial) 3 Other 3 a two patients were removed from study and no data is available; b prior therapies included systemic therapy, excludingRAI 131 , given at time of recurrence or metastasis with the exception of a minority of patients where testing was performed after adjuvant therapy. CUP, cancer of unknown primary; NSCLC, nonsmall cell lung cancer; GIST, gastrointestinal stromal tumor; GI, gastrointestinal; GE, gastroesophageal; ER, estrogen receptor; GU genitourinary. CDKN2A  CDKN2B  CDKN2C  CDKN1B  CCND1  CCND2  CCND3  CCNE  CDK4  CDK6  CDK8  CDK12  CEBPA  CHEK1  CHEK2  MED12  STAG2   ATM  ATR  BARD1  BLM  BRCA1  BRCA2  BRIP1  FANCA  FANCC  FANCD2  FANCF  FANCG  FANCL  MRE11A  MUTYH  PALB2  PRKDC  RAD50  RAD51   ATRX  CBFB  CDC73  CIC  CTCF  EP300  ERG  EWSR  FOXL2  GATA1  GATA2  GATA3  IRF4  JUN  MEF2B  MITF  MYC  MYCN  MYCL1  NKX2-1  RUNX1  SPEN  SOX2  SOX10  WT1  ZNF217  ZNF703   ASXL1  BAP1  DNMT3A  DOT1L  EZH2  KDM6A  KDM5C  KDM5A  MYST3  MLL2  SETD2   ALK  ABL1  AXL  BTK  CSF1R  DDR2  EPHA3  EPHA5  EPHB1  ERBB2  EGFR  ERBB4  FLT1  FLT3  FLT4  IGF1R  KIT  MET  NTRK1  NTRK2  NTRK3  PDGFRA  PDGFRB  RET  SRC  TGFBR2 Immunity 
